Research programme: small molecule therapeutics - Neuron23
Latest Information Update: 01 Jan 2021
At a glance
- Originator Neuron23; Origenis
- Class Antiparkinsonians; Small molecules
- Mechanism of Action LRRK2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Parkinson's disease
Highest Development Phases
- Preclinical Parkinson's disease
Most Recent Events
- 01 Jan 2021 Small molecule therapeutics - Neuron23 is available for licensing as of 01 Jan 2021. https://neuron23.com/partners/ (Neuron23 pipeline, December 2020)
- 16 Dec 2020 Neuron23 and Origenis agree to co-develop five small molecule therapeutics for Parkinson's disease (Neuron23 pipeline, December 2020)
- 16 Dec 2020 Preclinical trials in Parkinson's disease in USA (unspecified route)